Efficacy and safety of cefprozil and cefaclor on cutaneous infections;Eficacia e seguranca do cefprozil e cefaclor nas infeccoes cutaneas leves e moderadas

Anais Brasileiros de Dermatologia

Volumn 72, Issue 1, 1997, Pages 79-82

  Golcman, Benjamin ^a   Tuma, Sandra R ^a   Golcman, Ronaldo ^a   Schalka, Sérgio ^a   Gonzalez, Marjory A ^a  

^a NONE

Author keywords

bacterial infections; cefaclor; cephalosporins

Indexed keywords

CEFACLOR; CEFPROZIL; CEPHALOSPORIN DERIVATIVE;

ABSCESS; ADULT; ANOREXIA; ANXIETY; ARTICLE; BACTERIAL INFECTION; CELLULITIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; ECZEMA; FEMALE; HEADACHE; HUMAN; IMPETIGO; MALE; MORGANELLA MORGANII; RANDOMIZED CONTROLLED TRIAL; SCABIES; SKIN INFECTION; SOMNOLENCE; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES; TINEA PEDIS; VOMITING;

EID: 0030888207     PISSN: 03650596     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (6)

1. Gilman AG, Rall TW, Niels AS et al. eds. Goodman and Gilman's. The pharmacological bases of therapeuthics. 8 ed. Elmsford: Pergamon Pres, 1990:1024-134.
2. Cunha BA. Oral cephaslosporins for comuns infections. Emerg Med 1990;22:8998.
3. Jones RN, Barry AL and the Collaborative Antimicrobial Testing Group. BMY-28100, a new oral cephalosporin: antimicrobial activity against nearly 7000 recent clinical isolates, comparative potency with other oral agents and activity against betalactmase producing isolates. Diagn Microbiol Infect Dis 1988;9:11-26.
4. Hiraoka M, Masuyoshi S, Tomatsu L et al In vitro activity and betalactamase stability of the oral cephalosporins BMY 28100. Eur J Clin Microbiol Infect Dis 1987;6:559-63.
5. Wachs G, Rogan MP and the Cefprozil Multicenter Study Group. Cefprozil Vs Erytromicin for mild to moderate skin and skin structure infections. Infect Med 1992;9(Suppl E):57-65.
6. Parish LC, Doyle CA, Durham SJ, Wilber RB and the Cefprozil Multicenter Study Group. Cefprozil versus Cefaclor in the treatment of mild to moderate skin and skin infections. Clin Therapeutics 1992;14:458-69.